Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Oct 2017

Schvartsman Gustavo, Peng S Andrew, Bis Giorgios, Lee J Jack, Benveniste Marcelo F K, Zhang Jianjun, Roarty Emily B, Lacerda Lara, Swisher Stephen, Heymach John V, Fossella Frank V, William William N

Abstract excerpt

INTRODUCTION: Exploratory analysis of clinical trials in various tumor types have demonstrated potential improvements in overall response rate (ORR) to chemotherapy after exposure to vaccine-based immunotherapy. The objective of this retrospective study was to determine if single-agent chemotherapy (3rd-line or beyond) would yield improved ORR when given after exposure to programmed death-(ligand)1 inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Immunomodulation

Share to Immunotherapy

Share to Molecular Targeted Therapy

Share to Neoplasm Staging

Share to Survival Analysis

Source

Identifiers

PMID: 29191606
DOI: 10.1016/j.lungcan.2017.07.034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.PMID 29191606Read ↗

Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity Read ↗

Non–Small Cell Lung Cancer Metastatic Without Oncogenic AlterationsSemantic proximity Read ↗

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.Semantic proximity Read ↗

Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity Read ↗

Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors Following Disease Progression or RelapseSemantic proximity Read ↗

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.Semantic proximity Read ↗

Real-world survival outcomes to first-line chemoimmunotherapy and biomarker analysis in extensive-stage small-cell lung cancerSemantic proximity Read ↗

Early radiologic response after two cycles of neoadjuvant chemoimmunotherapy and pathologic outcomes in resectable non-small cell lung cancer: A multicenter retrospective studySemantic proximity Read ↗

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.Semantic proximity Read ↗

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.Semantic proximity Read ↗

Comparison of efficacy and safety of first-line treatment options for unresectable stage III non-small cell lung cancer: a retrospective analysisSemantic proximity Read ↗

Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.